# US 2018/0021334 A1 · Use of ergot alkaloids as an anthelmintic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021334 A1
- Document ID: US20180021334A1
- Status: Published application
- Kind: A1
- Application number: 15/596,776
- Filed: 2017-05-16
- Published: 2018-01-25
- Earliest claimed: 2016-05-16
- Assignees: Regents of the University of Minnesota
- Inventors: Jonathan Stephen Marchant; John David Chan
- Web page: https://patentgrep.com/patent/US20180021334A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A23K 20/132: containing only one nitrogen as hetero atom
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods for preventing, inhibiting or treating parasitic flatworm infection in a vertebrate are provided that include administering an effective amount of a composition comprising one or more ergot alkaloids, one or more lysergic acid amides, or one or more dimethoxyisoquinoline derivatives

## Claims

### Claim 1

A method of preventing, inhibiting or treating parasitic flatworm infection in a vertebrate, comprising: administering an effective amount of a composition comprising one or more ergot alkaloids, one or more lysergic acid amides, or one or more dimethoxyisoquinoline derivatives, or any combination thereof, wherein the ergot alkaloid is an agonist or partial agonist of Schistosoma serotonergic G-protein coupled receptor.

### Claim 2 (depends on 1)

The method of claim 1 wherein the ergot alkaloid or the lysergic acid amide is an agonist or partial agonist of Schistosoma mansoni serotonergic G-protein coupled receptor (Sm.5HTR), Schistosoma japonicum serotonergic G-protein coupled receptor (Sj.5HTR) or Schistosoma haematobium serotonergic G-protein coupled receptor (Sh.5HTR), or any combination thereof.

### Claim 3 (depends on 1)

The method of claim 1 wherein the ergot alkaloid comprises an ergopeptine.

### Claim 4 (depends on 1)

The method of claim 1 wherein a combination of ergot alkaloids, a combination of lysergic acid amides, or a combination of at least one ergot alkaloid and at least one lysergic acid amide is administered.

### Claim 5 (depends on 1)

The method of claim 1 wherein the vertebrate is a human.

### Claim 6 (depends on 1)

The method of claim 1 wherein the vertebrate is a non-human mammal.

### Claim 7 (depends on 1)

The method of claim 1 wherein the amount inhibits contractility, viability, egg laying (number of eggs laid), or egg production by the flatworm.

### Claim 8 (depends on 1)

The method claim 1 wherein the amount is effective to reduce schistosomiasis, neurocystcicerosis or clonochiasis.

### Claim 9 (depends on 1)

The method of claim 1 wherein the composition comprises a compound of formula (I):
wherein,
R1 is hydrogen, trifluoromethyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, or alkylaryl;
R2 is hydrogen, trifluoromethyl, halogen, cyano, nitro, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, alkylaryl, ORx, OCORx, ONRxRy, SRx, NRxRy, NRxORy, NRxNRxRy, NRxCORy, NRxCO2Ry, NRxSO2Ry, CORx, or CO2Rx;
R3 is hydrogen, trifluoromethyl, halogen, cyano, nitro, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, alkylaryl, ORx, OCORx, ONRxRy, SRx, NRxRy, NRxORy, NRxNRxRy, NRxCORy, NRxCO2Ry, NRxSO2Ry, CORx, or CO2Rx;
R4 is hydrogen, trifluoromethyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, or alkylaryl;
R5 is hydrogen, trifluoromethyl, halogen, cyano, nitro, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, alkylaryl, ORx, OCORx, ONRxRy, SRx, NRxRy, NRxORy, NRxNRxRy, NRxCORy, NRxCO2Ry, NRxSO2Ry, CORx, or CO2Rx;
Rx and Ry are independently at each occurrence hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, or alkylaryl;
X—Y is a carbon-carbon single bond or a carbon-carbon double bond;
deuterated analogs thereof,
or pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 1)

The method of claim 1 wherein the composition comprises a compound of formula (II):
wherein,
R6 is hydrogen, trifluoromethyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, or alkylaryl;
R7 is hydrogen, trifluoromethyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, or alkylaryl;
R8 is hydrogen, trifluoromethyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, or alkylaryl;
R9 is hydrogen, trifluoromethyl, halogen, cyano, nitro, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, alkylaryl, ORx, OCORx, ONRxRy, SRx, NRxRy, NRxORy, NRxNRxRy, NRxCORy, NRxCO2Ry, NRxSO2Ry, CORx, or CO2Rx;
Rx and Ry are independently at each occurrence hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, aryl, or alkylaryl;
X—Y is a carbon-carbon single bond or a carbon-carbon double bond;
A is a bond or NRx;
deuterated analogs thereof,
or pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 1)

The method of claim 1 wherein the compound is administered weekly.

### Claim 12 (depends on 1)

The method of claim 1 wherein the vertebrate is further administered caffeine.

### Claim 13 (depends on 1)

The method of claim 1 wherein the vertebrate is further administered praziquantel.

### Claim 14 (depends on 1)

The method of claim 1 wherein the composition is orally, intramuscularly, rectally, intravenously or intranasally administered.

### Claim 15 (depends on 1)

The method of claim 1 wherein composition is a tablet or animal feed.

### Claim 16 (depends on 1)

The method of claim 1 wherein the vertebrate is a human and the parasitic worm or helminth selected from the group consisting of Roundworm, Whipworm, Hookworm, Ascaris, Pinworm, Strongyloides, Schistosome, and Trematodes.

### Claim 17 (depends on 1)

The method of claim 1 wherein the worm is S. masoni, S. haemutobium, S. japanicum, S. mekongi or S. intercalatum.

### Claim 18 (depends on 1)

The method of claim 1 wherein the worm or helminth is resistant to praziquantel.

### Claim 19 (depends on 1)

The method of claim 1 wherein ergotamine, dihydroergotamine and lisuride are administered.

### Claim 20 (depends on 19)

The method of claim 19 wherein ergotamine, dihydroergotamine and lisuride are concurrently administered.
